The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Common Misconceptions Clarified: Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

Common Misconceptions Clarified: Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

March 23, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BALTIMORE—Often in rheumatology, technical terms and definitions represent more than just semantics. Indeed, having a shared understanding among clinicians of what constitutes a clinical disorder or disease can be essential to appropriately diagnose and treat patients. At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting at the Johns Hopkins University School of Medicine, Baltimore, Atul Deodhar, MD, professor of medicine in the Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, helped provide clarity on non-radiographic axial spondyloarthritis and other related topics.

You Might Also Like
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Ixekizumab Improves Outcomes of Ankylosing Spondylitis
  • FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis
Explore This Issue
April 2022
Also By This Author
  • Gut Instinct: Ankylosing Spondylitis & the Microbiome

Classification Criteria

In 2009, Rudwaleit et al. published a landmark article describing the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis.1 Contrary to popular belief, the term non-radiographic axial spondyloarthritis  (nr-axSpA) does not require the absence of sacroiliitis on imaging. Patients with definite radiographic sacroiliitis on X-rays (i.e., grade 2 bilateral or grade 3 or 4 unilateral sacroiliitis, according to the 1984 Modified New York Criteria for ankylosing spondylitis) and with at least one clinical feature of axial spondyloarthritis (axSpA) meet the definition for ankylosing spondylitis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Meanwhile, patients can meet criteria for nr-axSpa in a number of ways: 1) having acute (active) inflammation of the sacroiliac joints on magnetic resonance imaging (MRI) with at least one clinical feature of spondyloarthritis; 2) having grade 2 unilateral or grade 1 unilateral or bilateral sacroiliitis on X-rays and meeting two or more clinical features of axial spondyloarthritis; or 3) demonstrating positive HLA-B*27 and meeting two or more clinical features of axial spondyloarthritis.1

Dr. Deodhar made several insightful points on this subject. First, he noted that the distinction between radiographic and non-radiographic axial spondyloarthritis is somewhat arbitrary. If one clinician believes that X-rays for a patient show only unilateral grade 2 sacroiliitis but another clinician believes they show bilateral grade 2 sacroiliitis, then the same patient would be labeled with nr-axSpA in the first instance and radiographic axial spondyloarthritis in the second instance. It’s impossible to say which clinician’s assessment is truly correct, and thus the labeling of the condition is in the eye of the beholder.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Nevertheless, Dr. Deodhar explained that identifying patients with nr-axSpA is an important starting point in following the course of disease. Fewer than 5% of patients with nr-axSpA have self-limiting disease: 5–30% of patients will progress from non-radiographic to radiographic axial spondyloarthritis over 2–30 years.2 This makes sense when one realizes that patients with advanced spondyloarthritis, including end-stage such features as bamboo spine, were not born with these imaging findings, but progressed from more mild to more severe radiographic changes over the course of their lives.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Ankylosing Spondylitis, AS Resource Center, non-radiographic axial spondyloarthritis, spondyloarthritisIssue: April 2022

You Might Also Like:
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Ixekizumab Improves Outcomes of Ankylosing Spondylitis
  • FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)